San Francisco, CA

Bluejay Therapeutics develops innovative cures for infectious diseases. The first target indication is chronic HBV infection (CHBV). Bluejay has in-licensed three promising assets from Novartis that use different mechanisms to contribute to a functional cure for CHBV. Lead programs will begin clinical trials in 2022.


© Copyright RiverVest® All Rights Reserved.